PSE's gCOAS heralds breakthrough in computational oral absorption analysis
Formulation scientists can "bring new and better drugs to market earlier"
PSE today announced its new gCOAS® product for computational oral absorption at the Drug Development and Formulation Summit in Düsseldorf.
gCOAS, co-developed within the Systems-based Pharmaceutics (SbP) Alliance, is an analysis tool for a priori prediction of drug absorption in the human intestine as a function of product formulation parameters and ingestion conditions.
It provides formulation scientists with a tool that allows them to easily and quickly screen the performance of new formulations. The ultimate objective is to design a good dosage form in terms of amount of active pharmaceutical ingredient (API), particle size distribution of the API crystals, and other relevant attributes.
gCOAS aims to give unprecedented confidence in the accuracy of predictions of fractions absorbed using basic compound data, allowing more comprehensive early stage screening of promising candidate molecules and enabling the design of better formulations throughout the development lifecycle. These improved formulations reduce the risk to healthy volunteers and patients, as well as help reduce the number of trials, making it possible to bring new and better drugs to market earlier.
gCOAS is a key component of PSE’s Systems-based Pharmaceutics vision, in which the formulation and manufacturing decisions are based on their effect on the efficacy of the drug. The ultimate goal of SbP is to identify the drug formulation that gives you the desired bioavailability while satisfying manufacturing constraints such as flowability and content uniformity as early as possible in the development cycle.
Richard Longdon appointed chairman of PSE
AVEVA CEO joins board of rapidly-growing UK high-tech supplier to process industries
We are pleased to announce that Richard Longdon, CEO of AVEVA Group plc (www.aveva.com; LSE: AVV.L), the global provider of engineering software to the process industries, has been appointed as non-executive chairman of PSE. He succeeds outgoing Chairman Keith Guy, who is stepping down after more than 13 years in the position.
Richard joined AVEVA in 1984. He was part of the management buyout team in 1994, with responsibility for worldwide sales and marketing activities at the company's London Stock Exchange listing in 1996 and was appointed Group Chief Executive in 1999. Since then, he has overseen substantial growth of the company via a number of strategic acquisitions that have given AVEVA a consistent track record of growing revenues and profits over the long term.
Costas Pantelides, MD of PSE, says "We are immensely grateful for Keith's Guy's contribution to PSE since 2001. He has overseen the growth of the company from a small spin-out to the substantial and respected international organisation that it is today".
He adds "Richard Longdon brings in a wealth of experience and expertise in managing and delivering growth in an international technology company, which will be invaluable in taking PSE through the next stages of its development."
Richard Longdon says "I am very excited to be joining a company of the pedigree and reputation of PSE. The company and its products are already transforming the way the process industries around the world design and operate, and I look forward to playing my part in continuing and accelerating that success."
PSE's gPROMS advanced process modelling technology is widely used throughout the chemicals, energy, petrochemical, food and pharmaceuticals sectors to explore the process decision space rapidly and effectively and make better, faster and safer design and operating decisions. The company's expanding global customer base of Fortune 500 process industry companies is served by operations in the UK, USA, Switzerland, Japan and Korea, and agency relationships in key developing economies.